Ilan Shiloah
Board Member
Silexion Therapeutics Corp (SLXN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Ilan Shiloah
Ilan Shiloah is recorded as Board Member at Silexion Therapeutics Corp (SLXN). Silexion Therapeutics Corp reported in an 8-K filed September 19, 2024 that Ilan Shiloah resigned as independent director serving on the board of directors, effective September 16, 2024. Silexion Therapeutics Corp reported in an 8-K filed August 21, 2024 that Ilan Shiloah was appointed Director, effective August 15, 2024.
“On September 16, 2024, Ilan Shiloah, an independent director serving on the board of directors (the "Board") of Silexion Therapeutics Corp, a Cayman Islands exempted company (the "Company"), informed the Company that he has resigned from the Board, including from his membership on each of the committees of the Board— the audit committee, the compensation committee, and the corporate governance and nominating committee— effective immediately.”
“Pursuant to the appointment by New Silexion's shareholders prior to the Closing, the following persons constitute the Board effective upon the Closing: Ilan Hadar (Chairman), Dror Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy, and Ilan Shiloah.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-08-15–present
-
2024-08-15–2024-09-16
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Silexion Therapeutics Corp
Other people whose current roles at this company are on record from its filings.
- Ilan Hadar CEO, Chairman
- Mirit Horenshtein Hadar CFO
- Amnon Peled Board Member
- Avner Lushi Board Member
- Dror Abramov Board Member
- Ilan Levin Board Member
- Ruth Alon Board Member
- Shlomo Noy Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.